Quest Diagnostics (NYSE:DGX) Given New $154.00 Price Target at Robert W. Baird
Quest Diagnostics (NYSE:DGX – Free Report) had its price target hoisted by Robert W. Baird from $153.00 to $154.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a neutral rating on the medical research company’s stock. Several other analysts have also weighed in on the company. Barclays upped […]
More Stories
Concentric Wealth Management LLC Purchases 148 Shares of Union Pacific Co. (NYSE:UNP)
Concentric Wealth Management LLC grew its position in shares of Union Pacific Co. (NYSE:UNP – Free Report) by 0.8% during...
How Marco Rubio and Mike Waltz Could Shape Trump’s China Policy
By Terri Wu and Lilly Zhou WASHINGTON—Sen. Marco Rubio (R-Fla.) and Rep. Mike Waltz (R-Fla.) are set to have a...
Larson Financial Group LLC Acquires 6,246 Shares of NIKE, Inc. (NYSE:NKE)
Larson Financial Group LLC grew its stake in NIKE, Inc. (NYSE:NKE – Free Report) by 121.7% in the 3rd quarter,...
Prosperity Financial Group Inc. Grows Holdings in Elevance Health, Inc. (NYSE:ELV)
Prosperity Financial Group Inc. increased its holdings in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 13.5% during...
QCR (NASDAQ:QCRH) Reaches New 52-Week High Following Dividend Announcement
QCR Holdings, Inc. (NASDAQ:QCRH – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Monday...
Mirabella Financial Services LLP Buys 10,632 Shares of Skyworks Solutions, Inc. (NASDAQ:SWKS)
Mirabella Financial Services LLP raised its stake in Skyworks Solutions, Inc. (NASDAQ:SWKS – Free Report) by 210.6% during the third...